Please login to the form below

Not currently logged in
Email:
Password:

Baxalta

This page shows the latest Baxalta news and features for those working in and with pharma, biotech and healthcare.

Immunology keeps Shire figures solid as Takeda takeover nears

Immunology keeps Shire figures solid as Takeda takeover nears

$612m but the company’s haematology franchise – including haemophilia products acquired along with Baxalta in 2016 – down 1% to $951m.

Latest news

More from news
Approximately 16 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    quite as fast as Shire's move to take over Baxalta when it was spun out of Baxter in July 2015).  Paying $105 per share in cash (64% premium over

  • The good, the bad and the ugly The good, the bad and the ugly

    Shire’s incredible revenue growth of almost 57%, helped by its $32bn acquisition of Baxalta in 2016, lifted it into the top 20 for the first time in its history. ... However, investors fear that challenges in the $11bn haemophilia market could lead to

  • Deal Watch January 2017 Deal Watch January 2017

    Interestingly 2016 had opened with Shire's announcement that the Baxalta acquisition was going ahead resulting in one of the year's biggest headlines with its final value of £32bn.

  • A rare talent A rare talent

    The biggest of these moves was its $32bn acquisition of Baxalta, which was officially completed in June last year and elevated its position in orphan drugs, which it expects to account ... The combination of Shire and Baxalta was extremely transformative,

  • Deal Watch December 2016 Deal Watch December 2016

    In terms of headline figures (33 of the 39 deals announced financials) December came in at $29bn, second only to January 2016 at $42bn (which included the $32bn Shire-Baxalta deal). ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure

More from intelligence
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Mergers and acquisitions: agents for change

    even serial shakeups such as seen for Baxter-Baxalta-Shire-Takeda, these events transform the industry landscape, reshaping pipelines and reshuffling R&D priorities.

  • Bedrock Group Bedrock Group

    Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics